Sanofi buys Synthorx Inc for US$2.35bn
Sanofi will acquire Synthorx Inc to expand its immuno-oncology pipeline with THOR-707, an optimised IL-2 candidate.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1999 entries already.
Entries by Thomas Gabrielczyk
Meatable NV raises US$10m in seed funding
Meatable NV, a specialist for cultivated meat, has raised an additional US$10m in seed funding, bringing the company’s total funding to US$13m.
Big Pharma is cost driver of GAVI
Médecins Sans Frontières (MSF) called on the GAVI Vaccine Alliance not to pay huge subsidies to Big Pharma companies for pneumococcal vaccine
ImCheck Therapeutics SAS raises €48m
T cell agonist specialist ImCheck Therapeutics will use €48m (US$53m) from a Series B financing to push clincial pipeline of antibodies activating gamma-delta T-cells.
Pierre Fabre amends license agreement with Puma Biotechnology
Pierre Fabre SA and Puma Biotechnology, Inc. have broadened the geographic coverage of their license agreement on commercialisation of Nerlynx® (neratinib).
European circular bioeconomy fund near closing
The European Commission and the European Investment Bank (EIB) have selected ECBF Management GmbH as investment advisor for the €250m EU circular bioeconomy fund.
Researchers find new indication for cancer drug
French researchers have found MALT1 blockers not only to act on blood cancers but also to be effective as a treatment for glioblastoma.
Research team improves safety of LGMD2A gene therapy
Researchers have designed a limb girdle muscular dystrophy 2A gene therapy preventing cardiotoxicity of calpain3 gene transfer.
GeNeuro and Karolinska Institute collaborate in multiple sclerosis
Geneva-based GeNeuro SA announced a new clinical study of temelimab to treat patients with multiple sclerosis in collaboration with Karolinska Institute and ASC.
Tecentriq-Avastin combo hits endpoint in liver cancer
Roche AG said on Friday that its PD-L1 blocker Tecentriq plus its VEFG blocker Avastin improved progression-free survival versus sorafinib in a pivotal study in hepatocellular carcinoma (HCC) patients.